NavDx® is a blood test that detects human papilloma virus (HPV)-associated cancer by quantifying fragments of tumor-specific DNA shed by cells into the blood.
NavDx® measures the number of tumor-tissue modified virus (TTMV™) analytes present in the circulation by digital droplet PCR (ddPCR).
NavDx® distinguishes TTMV from other, non-cancer associated sources of HPV DNA.
- NavDx® has been clinically validated in a multi-year longitudinal study for head & neck cancer recurrence
- NavDx® is intended to provide information for the clinical management of HPV-related head and neck cancers.
- NavDx® has the potential to allow patients with recurrent disease to begin earlier treatment and spare disease-free patients from repeated invasive testing.